Form 4: ClearPoint Neuro Director Timothy T. Richards Reports Acquisition of Restricted Stock Units

Director Timothy T. Richards reports acquisition of 21,093 restricted stock units in ClearPoint Neuro, Inc.

Summary

• On May 16, 2024, Timothy T. Richards, a director of ClearPoint Neuro, Inc., reported the acquisition of 21,093 restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share of ClearPoint Neuro common stock.
• The RSUs vest on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2025 annual meeting of stockholders.
• Following the transaction, Richards directly owns 21,093 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it is a standard disclosure of stock unit acquisition. The acquisition itself can be seen as a slightly positive sign of director confidence.

Positives

• The acquisition of restricted stock units by a director signals confidence in the company's future performance.

Future Outlook

The vesting of the restricted stock units is contingent upon the earlier of the first anniversary of the grant date or the day immediately preceding the Company's 2025 annual meeting of stockholders.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, ensuring fair market practices.

Stakeholder Impact

• The acquisition of restricted stock units by a director can positively influence shareholder sentiment.

Key Dates